Brief: Oncolytics Announces Anal Cancer Cohort Of GOBLET Phase 1/2 Study Of Pelareorep And Atezolizumab Met Success Criteria For Efficacy
09/11/2023 12:40
Nov 9 (Reuters) - Oncolytics Biotech Inc ONC.TO :
* ONCOLYTICS ANNOUNCES THE ANAL CANCER COHORT OF THE GOBLET
PHASE
1/2 STUDY OF PELAREOREP AND ATEZOLIZUMAB HAS MET THE SUCCESS
CRITERIA FOR EFFICACY
Source text for Eikon: ID:nPnbBZZXTa
Further company coverage: ONC.TO
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Oncolytics Biotech
See all newsBrief: Oncolytics Biotech Files For Mixed Shelf Offering Of Up To $150 Million
Brief: Oncolytics Biotech® Announces Voluntary Delisting From The Toronto Stock Exchange
Advisory: Alert on global oncology breakthroughs tagged to multiple pharma firms withdrawn
Brief: Oncolytics Biotech® Appoints Former Ambrx Executive As Chief Business Officer
Brief: Oncolytics Biotech Appoints Former Ambrx Executive As Chief Business Officer